Australia markets open in 9 hours 44 minutes

Comera Life Sciences Holdings, Inc. (CMRA)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0893+0.0073 (+8.96%)
At close: 03:31PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.0820
Open0.0937
Bid0.0000 x 2200
Ask0.0000 x 1800
Day's range0.0878 - 0.0937
52-week range0.0300 - 2.1700
Volume43,510
Avg. volume200,303
Market cap2.746M
Beta (5Y monthly)0.45
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

    Dorothy Clarke Dorothy Clarke WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. “Dorothy’s extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way

  • GlobeNewswire

    Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

    – Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera’s global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – – Completed previously announced $4.1 million private placement of shares of Comera’s common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., N

  • GlobeNewswire

    Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference

    WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass. Yuhong Zeng, Ph.D., Director of Formulation at Comera,